Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Announces Financial Calendar for 2021

20191217 Financial calendar 2021 EN

Published 17 December 2020
Categorized as 2020, Press release

Transgene Announces Investor Meetings for January 2021

20201216 PR Investors Meeting agenda Jan 2021

Published 16 December 2020
Categorized as 2020, Press release

Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

20201203 – TG4001 mini oral prez ESMO IO EN

Published 3 December 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer

20201203 – Nomination Transgene – EN

Published 3 December 2020
Categorized as 2020, Press release

Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201109 Transgene BioInvent_SITC BT001_EN

Published 9 November 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020

20201109 – TG4001+avelumab presentation poster SITC – EN

Published 9 November 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene reports business update and end Q3 2020 financial position

20201105 Transgene Q3 business upradta EN

Published 5 November 2020
Categorized as 2020, Press release

Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit

20201105 TG – Neoantigen summit presentation

Published 5 November 2020
Categorized as 2020, Press release, TG4050

Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201027 – TG4001+avelumab abstract data SITC – EN

Published 27 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201019 TG4001+avelumab SITC – EN

Published 19 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Posts pagination

Newer posts Page 1 … Page 17 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu